Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20501

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20501)

Author(s): Wen xian Wang, Chunwei Xu, You-cai Zhu, Quxia Zhang, Yu Chen, Yong Fang, Hong Wang, Wu Zhuang, Yun-jian Huang, Meiyu Fang, Yinbin Zhang, Liping Wang, Huibao Zhang, Ying Zhou, Yu Zheng, Xugang Hu, Weiping Jiang, Gang Chen, Tangfeng Lv, Yong Song; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, Hangzhou, China; Department of Pathology, Fujian Medical University Cancer Hospital, Fuzhou, China; Zhejiang Rongjun Hospital, Jiaxing, China; Fujian Cancer Hospital, Fuzhou, China; Sir Run Run Shaw Hospital, Hangzhou, China; Affiliated Hospital of Academy of Military Medical Science, Beijing, China; Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China; Zhejiang Cancer Hospital, Hangzhou, China; The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China; Baotou Cancer Hospital, Baotou, China; Huashan Hospital, Fudan University, Shanghai, China; Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; South Campus, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China; Department of Respiratory Disease, The 903th Hospital of PLA, Hangzhou, China; Huadong Hospital, Fudan University, Shanghai, China; Jinling Hospital, Medical School of Nanjing University, Nanjing, China; Nanjing General Hospital of Nanjing Military Command (NGH)- Jinling Hospital, Nanjing, China

Abstract Disclosures

Abstract:

Background: Previous case series, retrospective studies and pooled survey studies have investigated the clinical efficacies of EGFR-TKIs in patients harboring EGFR uncommon mutations. However, part of patients with EGFR uncommon mutations do not exhibit objective responses to EGFR TKIs (primary resistance). The mechanism of primary resistance to icotinib in EGFR uncommon mutations NSCLC has not been clearly understood. Methods: We screened 3279 patients with NSCLC for EGFR uncommon mutations. Among them, 106 patients received icotinib treatment, and a total of 69 patients with stage IIIb-IV EGFR uncommon mutations NSCLC were undergoing tumor biopsies or blood withdrawing by the time of primary or acquiring to icotinib, in including formalin-fixed paraffin-embedded (FFPE) samples, serum samples and serous effusions. We used targeted NGS to detect genes status of patients. Results: Among 69 patients treated with icotinib, 69.57% (48/69) developed acquired resistance, and 30.43% (21/69) had primary resistance. Using the specimens at the baseline, there were 6(28.57%) patients with EGFR extracellular domain mutation, 5(23.81%) patients with BCL2L11 loss (BIM deletion polymorphism), 3(14.29%) patients with MET amplification, 1(4.76%) patient with ERBB2 amplification, 1(4.76%) patient with MYC amplification, 1(4.76%) patient with PTEN mutation, 1(4.76%) patient with PIK3CA mutation, and 3 (14.29%) patients with unknown status. Conclusions: EGFR extracellular domain mutation, BCL2L11 loss, PI3K-AKT-mTOR signaling pathway (PTEN, PIK3CA mutations), MET amplification, ERBB2 amplification or MYC amplification might contribute to molecular mechanisms of primary resistance to icotinib in EGFR uncommon mutations NSCLC. The complexity and heterogeneity of EGFR uncommon mutations NSCLC that may confer primary resistance to icotinib using NGS platform.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...